Skip to main content

BioFire Nabs Additional $20M Investment

NEW YORK (GenomeWeb News) – BioFire Diagnostics today said that Athyrium Opportunities Fund increased its investment in the company to $45 million.

Athyrium invested $25 million into BioFire in September. The new financing will go toward continued commercialization of and to meet growing demand for the Salt Lake City-based company's FilmArray molecular diagnostic platform.

The first panel for the platform, FilmArray Respiratory Panel, simultaneously tests for 17 viral targets and three bacterial targets in about one hour. BioFire said is making progress in bringing additional panels to the hospital market. Last month, it submitted its 510(k) application to the US Food and Drug Administration for its sepsis panel.

"The additional capital allows BioFire to simultaneously deepen our penetration into the hospital market with our molecular diagnostic platform, progress our blood culture ID panel through the FDA 510(k) approval process, and focus on bringing additional panels to market in the coming years," BioFire CEO Kirk Ririe said in a statement. "We continue to scale our organization to meet increasing demand for both the FilmArray RP and our pipeline panels, which we believe will further enhance the utility of our platform for the medical community."

The Scan

Pfizer-BioNTech Seek Full Vaccine Approval

According to the New York Times, Pfizer and BioNTech are seeking full US Food and Drug Administration approval for their SARS-CoV-2 vaccine.

Viral Integration Study Critiqued

Science writes that a paper reporting that SARS-CoV-2 can occasionally integrate into the host genome is drawing criticism.

Giraffe Species Debate

The Scientist reports that a new analysis aiming to end the discussion of how many giraffe species there are has only continued it.

Science Papers Examine Factors Shaping SARS-CoV-2 Spread, Give Insight Into Bacterial Evolution

In Science this week: genomic analysis points to role of human behavior in SARS-CoV-2 spread, and more.